FluoGuide A/S (STO:FLUO)

Sweden flag Sweden · Delayed Price · Currency is SEK
41.10
-0.80 (-1.91%)
Jun 4, 2025, 5:11 PM CET
-12.37%
Market Cap 570.68M
Revenue (ttm) 574.48K
Net Income (ttm) -44.06M
Shares Out 13.62M
EPS (ttm) -3.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,800
Average Volume 5,484
Open 40.10
Previous Close 41.90
Day's Range 40.10 - 41.60
52-Week Range 29.10 - 57.00
Beta 1.11
RSI 49.46
Earnings Date May 28, 2025

About FluoGuide

FluoGuide A/S, a clinical stage biotechnology company, focuses on developing drugs for surgical outcomes by making cancer fluorescent in Denmark. Its lead product candidate is FG001, which is in Phase IIa and IIb for the treatment of high-grade glioma; Phase II clinical trial for the treatment of lung cancer, and head and neck cancer. FluoGuide A/S was incorporated in 2018 and is headquartered in Copenhagen, Denmark. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 8
Stock Exchange Nasdaq Stockholm
Ticker Symbol FLUO
Full Company Profile

Financial Performance

In 2024, FluoGuide's revenue was 385,000, a decrease of -8.98% compared to the previous year's 423,000. Losses were -28.96 million, -24.54% less than in 2023.

Financial numbers in DKK Financial Statements

News

There is no news available yet.